indapamide has been researched along with Cardiovascular Diseases in 44 studies
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was a subsidiary analysis of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS)--a randomized, placebo-controlled trial that established the beneficial effects of blood pressure--lowering in a heterogeneous group of patients with cerebrovascular disease." | 9.11 | Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Anderson, C; Arima, H; Chalmers, J; Colman, S; Hart, RG; MacMahon, S; Neal, B; Rodgers, A; Woodward, M, 2005) |
| "To study effects of perindopril, indapamid and their combination on stratification of essential hypertension (EH) risk factors." | 9.09 | [Effects of perindopril and its combination with indapamide on risk stratification in patients with hypertension]. ( Ol'binskaia, LI; Zheleznykh, EA, 2001) |
| "A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension." | 8.87 | Perindopril for the treatment of hypertension. ( Ghiadoni, L, 2011) |
| "Hypertension is an important risk factor for cardiovascular complications and the need to treat this condition has been well established." | 6.47 | Combination perindopril/indapamide for the treatment of hypertension: a review. ( de Leeuw, PW, 2011) |
| " The fixed dosage of a once-daily tablet, ensures optimal ease of use and enhances patient compliance." | 6.43 | Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. ( Gosse, P, 2006) |
| "The Hypertension in the Very Elderly Trial (HYVET) was a double blind placebo-controlled trial of antihypertensive treatment (indapamide SR 1." | 5.14 | Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis. ( Beckett, N; Bulpitt, C; Clarke, R; Fletcher, A; Forette, F; Peters, R; Poulter, R; Ritchie, C; Tuomilehto, J; Waldman, A; Walton, I, 2009) |
| "This study was a subsidiary analysis of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS)--a randomized, placebo-controlled trial that established the beneficial effects of blood pressure--lowering in a heterogeneous group of patients with cerebrovascular disease." | 5.11 | Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. ( Anderson, C; Arima, H; Chalmers, J; Colman, S; Hart, RG; MacMahon, S; Neal, B; Rodgers, A; Woodward, M, 2005) |
| "To study effects of perindopril, indapamid and their combination on stratification of essential hypertension (EH) risk factors." | 5.09 | [Effects of perindopril and its combination with indapamide on risk stratification in patients with hypertension]. ( Ol'binskaia, LI; Zheleznykh, EA, 2001) |
| "A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension." | 4.87 | Perindopril for the treatment of hypertension. ( Ghiadoni, L, 2011) |
| " Results from HYVET (Hypertension in the Very Elderly Trial) showed that, at 2-year follow-up, antihypertensive drug therapy with indapamide, plus perindopril if needed, reduced fatal or nonfatal stroke by 30%, fatal stroke by 39%, all-cause mortality by 21%, cardiovascular death by 23%, and heart failure by 64%." | 3.74 | Older age should not be a barrier to the treatment of hypertension. ( Aronow, WS, 2008) |
| "5 mg of indapamide retard with or without addition of 2-4 mg of perindopril, 30% lowering of risk of development of fatal and nonfatal stroke (95% confidence interval [CI] -1 to 51, p=0." | 3.74 | [Arterial hypertension in persons older than 80 years: the problem can be successfully solved]. ( Batyraliev, TA; Fettser, DV; Ishlek, M; Preobrazhenskiĭ, DV; Sidorenko, BA, 2008) |
| " While randomized trials have demonstrated that blood pressure lowering reduces vascular complications in subjects with type 2 diabetes and hypertension, ADVANCE was designed to determine whether the addition of a fixed combination of perindopril and indapamide, on top of comprehensive and effective cardiovascular treatments and glucose control therapy, would produce further benefits, irrespective of the initial blood pressure." | 3.74 | Advances in reducing the burden of vascular disease in type 2 diabetes. ( Chalmers, J; Joshi, R; Patel, A, 2008) |
| "Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes." | 2.94 | The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020) |
| "11,140 participants with type 2 diabetes, from the ADVANCE trial, were randomized to perindopril-indapamide or matching placebo." | 2.77 | Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. ( Beulens, JW; Chalmers, J; Cooper, ME; Grobbee, DE; Harrap, S; Kengne, AP; Mancia, G; Neal, B; Patel, A; Poulter, N; van der Schouw, YT; van Dieren, S; Woodward, M; Zoungas, S, 2012) |
| "depression is common in elderly people and may be associated with increased cardiovascular risk and incident dementia." | 2.75 | Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET). ( Beckett, N; Bulpitt, C; Fletcher, A; Grimley-Evans, J; McCormack, T; Nunes, M; Peters, R; Pinto, E; Potter, J; Swift, C, 2010) |
| "In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events." | 2.75 | Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. ( Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S, 2010) |
| "Hypertension is an important risk factor for cardiovascular complications and the need to treat this condition has been well established." | 2.47 | Combination perindopril/indapamide for the treatment of hypertension: a review. ( de Leeuw, PW, 2011) |
| " The fixed dosage of a once-daily tablet, ensures optimal ease of use and enhances patient compliance." | 2.43 | Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. ( Gosse, P, 2006) |
| " We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes." | 1.43 | Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016) |
| "Perindopril/indapamide was well tolerated with no significant changes in laboratory parameters being observed." | 1.37 | Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. ( Pella, D, 2011) |
| "Factors that must be considered for the treatment of hypertension in patients, particularly with type 2 diabetes." | 1.31 | [Reflexion of French experts on the key points of the symposium]. ( Dubourg, O; Forette, F; Hanon, O; Mallion, JM; Marre, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (50.00) | 29.6817 |
| 2010's | 19 (43.18) | 24.3611 |
| 2020's | 3 (6.82) | 2.80 |
| Authors | Studies |
|---|---|
| Podzolkov, VI | 1 |
| Bragina, AЕ | 1 |
| Rodionova, YN | 1 |
| Bragina, GI | 1 |
| Bykova, EE | 1 |
| Lee, AK | 1 |
| Woodward, M | 12 |
| Wang, D | 1 |
| Ohkuma, T | 4 |
| Warren, B | 1 |
| Sharrett, AR | 1 |
| Williams, B | 3 |
| Marre, M | 7 |
| Hamet, P | 8 |
| Harrap, S | 6 |
| Mcevoy, JW | 2 |
| Chalmers, J | 13 |
| Selvin, E | 2 |
| Tian, J | 1 |
| Cooper, M | 2 |
| Mancia, G | 5 |
| Poulter, N | 7 |
| Wang, JG | 1 |
| Zoungas, S | 9 |
| Jun, M | 1 |
| Rodgers, A | 3 |
| Cooper, ME | 2 |
| Glasziou, P | 2 |
| Neal, B | 6 |
| Perkovic, V | 1 |
| Pereira, BC | 1 |
| Isreb, A | 1 |
| Forbes, RT | 1 |
| Dores, F | 1 |
| Habashy, R | 1 |
| Petit, JB | 1 |
| Alhnan, MA | 1 |
| Oga, EF | 1 |
| Rahman, F | 1 |
| Muntner, P | 1 |
| Konig, M | 1 |
| Lamos, EM | 1 |
| Stein, SA | 1 |
| Davis, SN | 1 |
| Beckett, N | 3 |
| Peters, R | 4 |
| Leonetti, G | 1 |
| Duggan, J | 1 |
| Fagard, R | 1 |
| Thijs, L | 2 |
| Narkiewicz, K | 1 |
| McCormack, T | 2 |
| Banya, W | 2 |
| Fletcher, A | 3 |
| Bulpitt, C | 3 |
| van der Leeuw, J | 2 |
| Visseren, FL | 2 |
| Kengne, AP | 5 |
| van der Graaf, Y | 2 |
| MacMahon, S | 2 |
| Grobbee, DE | 5 |
| Thomopoulos, C | 1 |
| Parati, G | 1 |
| Zanchetti, A | 1 |
| Hirakawa, Y | 1 |
| Matthews, DR | 1 |
| Patel, A | 6 |
| Grobbee, R | 1 |
| Jardine, M | 1 |
| Heller, S | 3 |
| Agnew, T | 1 |
| Tropeano, AI | 2 |
| Katsahian, S | 1 |
| Molle, D | 1 |
| Grimaldi, A | 1 |
| Laurent, S | 2 |
| Waeber, B | 1 |
| Burnier, M | 1 |
| Lüscher, T | 1 |
| Hess, O | 1 |
| Aronow, WS | 1 |
| Lundberg, GD | 1 |
| Hedner, T | 1 |
| Kjeldsen, S | 1 |
| Oparil, S | 1 |
| Narkiewics, K | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Batyraliev, TA | 1 |
| Fettser, DV | 1 |
| Ishlek, M | 1 |
| Forette, F | 3 |
| Tuomilehto, J | 1 |
| Ritchie, C | 1 |
| Walton, I | 1 |
| Waldman, A | 1 |
| Clarke, R | 1 |
| Poulter, R | 1 |
| Mourad, JJ | 1 |
| Le Jeune, S | 1 |
| Rump, LC | 1 |
| Nitschmann, S | 1 |
| Colagiuri, S | 2 |
| Pan, CY | 1 |
| Pinto, E | 1 |
| Swift, C | 1 |
| Potter, J | 1 |
| Nunes, M | 1 |
| Grimley-Evans, J | 1 |
| Batty, GD | 1 |
| Li, Q | 1 |
| Czernichow, S | 1 |
| Huxley, R | 1 |
| de Galan, BE | 1 |
| Harrap, SB | 1 |
| Angeli, F | 1 |
| Reboldi, G | 1 |
| Verdecchia, P | 1 |
| Travert, F | 1 |
| Lievre, M | 1 |
| Ghiadoni, L | 1 |
| de Leeuw, PW | 1 |
| Pella, D | 1 |
| van Dieren, S | 1 |
| Beulens, JW | 1 |
| van der Schouw, YT | 1 |
| Kaplan, NM | 1 |
| Mallion, JM | 1 |
| Hanon, O | 1 |
| Dubourg, O | 1 |
| Toblli, JE | 1 |
| DeRosa, G | 1 |
| Rivas, C | 1 |
| Cao, G | 1 |
| Piorno, P | 1 |
| Pagano, P | 1 |
| Forcada, P | 1 |
| Arima, H | 1 |
| Hart, RG | 1 |
| Colman, S | 1 |
| Anderson, C | 2 |
| Gosse, P | 1 |
| Boutouyrie, P | 1 |
| Scheen, AJ | 1 |
| Krzesinski, JM | 1 |
| Joshi, R | 1 |
| Beckett, NS | 1 |
| Fletcher, AE | 1 |
| Staessen, JA | 1 |
| Liu, L | 1 |
| Dumitrascu, D | 1 |
| Stoyanovsky, V | 1 |
| Antikainen, RL | 1 |
| Nikitin, Y | 1 |
| Belhani, A | 1 |
| Rajkumar, C | 1 |
| Bulpitt, CJ | 1 |
| Ol'binskaia, LI | 1 |
| Zheleznykh, EA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure[NCT00751972] | 140 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| The Hypertension in the Very Elderly Trial (HYVET)[NCT00122811] | Phase 4 | 4,000 participants (Anticipated) | Interventional | 2000-11-30 | Active, not recruiting | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| Essential Arterial Hypotension and Allostasis Registry[NCT02018497] | 5,000 participants (Anticipated) | Observational [Patient Registry] | 1995-01-31 | Recruiting | |||
| Estudio RioplateNsE Sobre Telemonitoreo en hIpertensos No-controlAdos[NCT02730052] | 0 participants (Actual) | Interventional | 2016-12-31 | Withdrawn (stopped due to Centers recruited poorly) | |||
| Morbidity and Mortality Based on Blood Pressure and Arterial Stiffness in Institutionalized Persons Aged 80 and Over: Study PARTAGE (Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population).[NCT00901355] | 1,130 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The 6MWT is a simple test which does not require expensive equipment or advanced training for technicians. The test involves asking the patient to walk the longest distance possible in a set interval of 6 min, through a walking course (corridor) preferably 30-m long. The patient can stop or slow down at any time and then resume walking, depending on his/her degree of fatigue.~A longer distance walked is indicative of a better outcome." (NCT00751972)
Timeframe: Baseline and 180 Days
| Intervention | meters (Mean) |
|---|---|
| HeartWare® VAS | 150.14 |
"The EQ-5D is a standardized instrument for use as a generic measure of the quality of health-related life and of health outcome.~The EuroQoL EQ-5D is a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.~Scores are transformed to a range of 0-100, in which higher scores reflect better health status." (NCT00751972)
Timeframe: Baseline and 180 Days
| Intervention | units on a EuroQol EQ-5D scale (Mean) |
|---|---|
| HeartWare® VAS | 29.53 |
"KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life for patients with congestive heart failure. It is a predictive tool that tracks how patients are doing if they have weakened heart muscle due to prior heart attacks, heart valve problems, viral infections, or other causes.~The KCCQ's questions are used to calculate scores in ten domains:~Physical Limitation, Symptom Stability, Frequency, Burden and Total Symptom. Social Limitation, Self-Efficacy, Quality of Life, and Clinical Summary. Overall Summary: a combined measure of all the above~For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status." (NCT00751972)
Timeframe: Baseline and 180 Days
| Intervention | units on a KCCQ scale (Mean) |
|---|---|
| HeartWare® VAS | 30.94 |
All subjects will be followed for date of death until 180 days. (NCT00751972)
Timeframe: 180 Days
| Intervention | Percentage of participants with survival (Number) |
|---|---|
| HeartWare® VAS | 94.3 |
| Contemporaneous Control | 91.2 |
The primary endpoint is success at 180 days which is defined as alive on the originally implanted HeartWare® LVAD or transplanted or explanted for recovery. A patient must survive 60 days post-explant for recovery to be considered successful. (NCT00751972)
Timeframe: 180 days
| Intervention | Percentage of participants with success (Number) |
|---|---|
| HeartWare® VAS | 90.7 |
| Contemporaneous Control | 90.1 |
Adverse events are only provided for patients who received a HeartWare Ventricular Assist Device (HeartWare® VAS). Adverse events as described by INTERMACS for the contemporaneous control population were not a part of the agreement for analysis and thus not provided by INTERMACS, and so not included in the Adverse Event Module and relevant Outcome Measures for comparison. (NCT00751972)
Timeframe: 180 Days
| Intervention | percentage of patients (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bleeding requiring reoperation | Infections - Local | Infections - Driveline | Infections - Sepsis | Neurologic Event-Ischemic Cerebrovascular accident | Neurologic Event-Hemorrhagic CVA | Neurologic Event - Transient Ischemic Attack(TIA)A | Right Heart Failure - requiring Inotropes | Right Heart Failure - requiring RVAD | Respiratory Dysfunction | Arterial Thromboembolism | Venous Thromboembolism | Renal Dysfunction | Hepatic Dysfunction | Hemolysis | |
| HeartWare® VAS | 17.1 | 25.0 | 12.1 | 11.4 | 7.1 | 4.3 | 4.3 | 16.0 | 2.9 | 19.3 | 2.9 | 6.4 | 5.7 | 2.9 | 3.6 |
The INTERMACS event device malfunction defined a failure of the HeartWare VAS as either pump failure or non-pump failure. (NCT00751972)
Timeframe: 180 Days
| Intervention | Number of events (Number) | |
|---|---|---|
| Pump Failure (exchange) | Non pump failure | |
| HeartWare® VAS | 7 | 19 |
7 reviews available for indapamide and Cardiovascular Diseases
| Article | Year |
|---|---|
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2013 |
Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2015 |
Perindopril for the treatment of hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardi | 2011 |
Combination perindopril/indapamide for the treatment of hypertension: a review.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hyperte | 2011 |
What matters in ADVANCE and ADVANCE-ON.
Topics: Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabete | 2012 |
Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Pulse pressure reduction and cardiovascular protection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardiovascular Di | 2006 |
17 trials available for indapamide and Cardiovascular Diseases
| Article | Year |
|---|---|
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin | 2020 |
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2 | 2020 |
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiovascular Diseases; Creatinine; Diabe | 2019 |
Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes | 2019 |
Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial.
Topics: Age Factors; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; De | 2014 |
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell | 2015 |
Lowering of brachial pulse pressure in 9379 hypertensives with type 2 diabetes and reduction of cardiovascular events.
Topics: Antihypertensive Agents; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Cohort Studies; D | 2008 |
Vascular risk factors and cognitive function among 3763 participants in the Hypertension in the Very Elderly Trial (HYVET): a cross-sectional analysis.
Topics: Aged, 80 and over; Antihypertensive Agents; Cardiovascular Diseases; Cognition Disorders; Comorbidit | 2009 |
The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2010 |
Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. Data from the Hypertension in the Very Elderly Trial (HYVET).
Topics: Aged, 80 and over; Antihypertensive Agents; Cardiovascular Diseases; Dementia; Depression; Female; G | 2010 |
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-A | 2010 |
Contemporary model for cardiovascular risk prediction in people with type 2 diabetes.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Asia; Australasia; Blood Glucose; Canad | 2011 |
Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2012 |
Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Fibr | 2005 |
[Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Di | 2007 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Treatment of hypertension in patients 80 years of age or older.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
[Effects of perindopril and its combination with indapamide on risk stratification in patients with hypertension].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diuretics; Drug Therapy, Combination; Female; Huma | 2001 |
20 other studies available for indapamide and Cardiovascular Diseases
| Article | Year |
|---|---|
[Tactics of antihypertensive therapy during COVID-19 pandemic].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; COVID-19 | 2021 |
'Temporary Plasticiser': A novel solution to fabricate 3D printed patient-centred cardiovascular 'Polypill' architectures.
Topics: Amlodipine; Cardiovascular Agents; Cardiovascular Diseases; Chemistry, Pharmaceutical; Crystallizati | 2019 |
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2016 |
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations | 2016 |
Slow release diuretics save lives.
Topics: Aged, 80 and over; Cardiovascular Diseases; Delayed-Action Preparations; Diuretics; Humans; Hyperten | 2008 |
[Need of antihypertensive therapy in patients aged 80 years or more].
Topics: Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, C | 2008 |
Older age should not be a barrier to the treatment of hypertension.
Topics: Age Factors; Aged, 80 and over; Aging; Antihypertensive Agents; Cardiovascular Diseases; Drug Therap | 2008 |
Study shows benefit of hypertension help after 80.
Topics: Aged, 80 and over; Aging; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hypertension; In | 2008 |
You should treat patients over the age of 80 who have hypertension.
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2008 |
Management of older hypertensive patients.
Topics: Age Factors; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Ch | 2008 |
[Arterial hypertension in persons older than 80 years: the problem can be successfully solved].
Topics: Age Factors; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; C | 2008 |
Heart protection: a key target in the management of patients with diabetes.
Topics: Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Humans; Hypertension; Indapamide; P | 2009 |
[Treatment of hypertension in patients older than 80 years].
Topics: Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2009 |
More than a REASON to use arterial stiffness as risk marker and therapeutic target in hypertension.
Topics: Antihypertensive Agents; Aorta; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial Artery; Card | 2011 |
Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme.
Topics: Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood | 2011 |
[The challenge to treat hypertensive patients with type 2 diabetes].
Topics: Adult; Albuminuria; Antihypertensive Agents; Body Mass Index; Cardiovascular Diseases; Diabetes Mell | 2002 |
[Reflexion of French experts on the key points of the symposium].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Cardiova | 2003 |
Advances in reducing the burden of vascular disease in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type | 2008 |
[Results of ADVANCE trial conducted in type 2 diabetic patients].
Topics: Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Europe; | 2008 |